Jemal A, Siegel R, Ward E et al.. Cancer statistics, 2008. CA Cancer J Clin 2008;58:71–96.

• PubMed
JemalASiegelRWardE. Cancer statistics, 2008. CA Cancer J Clin 2008;58:71–96. )| false
• Search Google Scholar
• Export Citation

Jones RH, Vasey PA. Part I: testicular cancer—management of early disease. Lancet Oncol 2003;4:730–737.

• PubMed
JonesRHVaseyPA. Part I: testicular cancer—management of early disease. Lancet Oncol 2003;4:730–737. )| false
• Search Google Scholar
• Export Citation

Fossa SD, Chen J, Schonfeld SJ et al.. Risk of contralateral testicular cancer: a population based study of 29,515 US men. J Natl Cancer Inst 2005;97:1056–1066.

• PubMed
FossaSDChenJSchonfeldSJ. Risk of contralateral testicular cancer: a population based study of 29,515 US men. J Natl Cancer Inst 2005;97:1056–1066. )| false
• Search Google Scholar
• Export Citation

Jones WG, Fossa SD, Mead GM et al.. Randomized trial of 30 versus 20 Gy in the adjuvant treatment of stage I testicular seminoma: a report on Medical Research Council Trial TE18, European Organisation for the Research and Treatment of Cancer Trial 30942 (ISRCTN18525328). J Clin Oncol 2005;23:1200–1208.

• PubMed
JonesWGFossaSDMeadGM. Randomized trial of 30 versus 20 Gy in the adjuvant treatment of stage I testicular seminoma: a report on Medical Research Council Trial TE18, European Organisation for the Research and Treatment of Cancer Trial 30942 (ISRCTN18525328). J Clin Oncol 2005;23:1200–1208. )| false
• Search Google Scholar
• Export Citation

Oliver RT, Mason MD, Mead GM et al.. Radiotherapy versus single-dose carboplatin in adjuvant treatment of stage I seminoma: a randomized trial. Lancet 2005;366:293–300.

• PubMed
OliverRTMasonMDMeadGM. Radiotherapy versus single-dose carboplatin in adjuvant treatment of stage I seminoma: a randomized trial. Lancet 2005;366:293–300. )| false
• Search Google Scholar
• Export Citation

Oliver RT, Mead GM & Fogarty PJ et al. Radiotherapy versus carboplatin for stage I seminoma: updated analysis of the MRC/EORTC randomized trial (ISRCTN27163214) [abstract]. J Clin Oncol 2008;26:(Suppl 1):Abstract 1.

• PubMed
OliverRTMeadGMFogartyPJ Radiotherapy versus carboplatin for stage I seminoma: updated analysis of the MRC/EORTC randomized trial (ISRCTN27163214) [abstract]. J Clin Oncol 2008;26:(Suppl 1):Abstract 1. )| false
• Search Google Scholar
• Export Citation

Alomary I, Samant R, Gallant V. Treatment of stage I seminoma: a 15 year review. Urol Oncol 2006;24:180–183.

• PubMed
AlomaryISamantRGallantV. Treatment of stage I seminoma: a 15 year review. Urol Oncol 2006;24:180–183. )| false
• Search Google Scholar
• Export Citation

Gospodarowicz M, Sturgeon JF, Jewitt MA. Early stage and advanced seminoma: role of radiation therapy, surgery, and chemotherapy. Semin Oncol 1998;25:160–173.

• PubMed
GospodarowiczMSturgeonJFJewittMA. Early stage and advanced seminoma: role of radiation therapy, surgery, and chemotherapy. Semin Oncol 1998;25:160–173. )| false
• Search Google Scholar
• Export Citation

de Wit R, Roberts JT, Wilkinson PM et al.. Equivalence of three or four cycles of bleomycin, etoposide, and cisplatin chemotherapy and of a 3- or 5-day schedule in good-prognosis germ cell cancer: a randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group and the Medical Research Council. J Clin Oncol 2001;19:1629–1640.

• PubMed
de WitRRobertsJTWilkinsonPM. Equivalence of three or four cycles of bleomycin, etoposide, and cisplatin chemotherapy and of a 3- or 5-day schedule in good-prognosis germ cell cancer: a randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group and the Medical Research Council. J Clin Oncol 2001;19:1629–1640. )| false
• Search Google Scholar
• Export Citation

Loehrer PJ Sr, Johnson D, Elson P et al.. Importance of bleomycin in favorable-prognosis disseminated germ cell tumors: an Eastern Cooperative Oncology Group trial. J Clin Oncol 1995;13:470–476.

• PubMed
LoehrerPJ SrJohnsonDElsonP. Importance of bleomycin in favorable-prognosis disseminated germ cell tumors: an Eastern Cooperative Oncology Group trial. J Clin Oncol 1995;13:470–476. )| false
• Search Google Scholar
• Export Citation

Bajorin DF, Sarosdy MF, Pfister DG et al.. Randomized trial of etoposide and cisplatin versus etoposide and carboplatin in patients with good-risk germ cell tumors: a multiinstitutional study. J Clin Oncol 1993;11:598–606.

• PubMed
BajorinDFSarosdyMFPfisterDG. Randomized trial of etoposide and cisplatin versus etoposide and carboplatin in patients with good-risk germ cell tumors: a multiinstitutional study. J Clin Oncol 1993;11:598–606. )| false
• Search Google Scholar
• Export Citation

Kondagunta GV, Bacik J, Bajorin D et al.. Etoposide and cisplatin chemotherapy for metastatic good-risk germ cell tumors. J Clin Oncol 2005;23:9290–9294.

• PubMed
KondaguntaGVBacikJBajorinD. Etoposide and cisplatin chemotherapy for metastatic good-risk germ cell tumors. J Clin Oncol 2005;23:9290–9294. )| false
• Search Google Scholar
• Export Citation

Becherer A, De Santis M, Karanikas G et al.. FDG PET is superior to CT in the prediction of viable tumour in post-chemotherapy seminoma residuals. Eur J Radiol 2005;54:284–288.

• PubMed
BechererADe SantisMKaranikasG. FDG PET is superior to CT in the prediction of viable tumour in post-chemotherapy seminoma residuals. Eur J Radiol 2005;54:284–288. )| false
• Search Google Scholar
• Export Citation

Warde P, Gospodarowicz MK, Panzarella T et al.. Stage I testicular seminoma: results of adjuvant irradiation and surveillance. J Clin Oncol 1995;13:2255–2262.

• PubMed
WardePGospodarowiczMKPanzarellaT. Stage I testicular seminoma: results of adjuvant irradiation and surveillance. J Clin Oncol 1995;13:2255–2262. )| false
• Search Google Scholar
• Export Citation

Puc HS, Heelan R, Mazumdar M et al.. Management of residual mass in advanced seminoma: results and recommendations from the Memorial Sloan-Kettering Cancer Center. J Clin Oncol 1998;14:454–460.

• PubMed
PucHSHeelanRMazumdarM. Management of residual mass in advanced seminoma: results and recommendations from the Memorial Sloan-Kettering Cancer Center. J Clin Oncol 1998;14:454–460. )| false
• Search Google Scholar
• Export Citation

Mencel PJ, Motzer RJ, Mazumdar M et al.. Advanced seminoma: treatment results, survival, and prognostic factors in 142 patients. J Clin Oncol 1994;12:120–126.

• PubMed
MencelPJMotzerRJMazumdarM. Advanced seminoma: treatment results, survival, and prognostic factors in 142 patients. J Clin Oncol 1994;12:120–126. )| false
• Search Google Scholar
• Export Citation

Sheinfeld J, Herr H. Role of surgery in management of germ-cell tumors. Semin Oncol 1998;25:203–209.

• PubMed
SheinfeldJHerrH. Role of surgery in management of germ-cell tumors. Semin Oncol 1998;25:203–209. )| false
• Search Google Scholar
• Export Citation

Carver BS, Sheinfeld J. The current status of laparoscopic retroperitoneal lymph node dissection for non-seminomatous germ-cell tumors. Nat Clin Pract Urol 2005;2:330–335.

• PubMed
CarverBSSheinfeldJ. The current status of laparoscopic retroperitoneal lymph node dissection for non-seminomatous germ-cell tumors. Nat Clin Pract Urol 2005;2:330–335. )| false
• Search Google Scholar
• Export Citation

Davis BE, Herr HW, Fair WR et al.. The management of patients with nonseminomatous germ-cell tumors of the testis with serologic disease only after orchiectomy. J Urol 1994;152:111–114.

• PubMed
DavisBEHerrHWFairWR. The management of patients with nonseminomatous germ-cell tumors of the testis with serologic disease only after orchiectomy. J Urol 1994;152:111–114. )| false
• Search Google Scholar
• Export Citation

Culine S, Theodore C, Terrier-Lacombe MJ, Droz JP. Primary chemotherapy in patients with nonseminomatous germ cell tumors of the testis and biological disease only after orchiectomy. J Urol 1996;155:1296–1298.

• PubMed
CulineSTheodoreCTerrier-LacombeMJDrozJP. Primary chemotherapy in patients with nonseminomatous germ cell tumors of the testis and biological disease only after orchiectomy. J Urol 1996;155:1296–1298. )| false
• Search Google Scholar
• Export Citation

Foster R, Bihrle R. Current status of retroperitoneal lymph node dissection and testicular cancer: when to operate. Cancer Control 2002;9:277–283.

• PubMed
FosterRBihrleR. Current status of retroperitoneal lymph node dissection and testicular cancer: when to operate. Cancer Control 2002;9:277–283. )| false
• Search Google Scholar
• Export Citation

Motzer RJ, Sheinfeld J, Mazumdar M et al.. Etoposide and cisplatin adjuvant therapy for patients with pathologic stage II germ-cell tumors. Classic Papers and Current Comments: Highlights of Genitourinary Cancer Research 1998b;2:455–459.

• PubMed
MotzerRJSheinfeldJMazumdarM. Etoposide and cisplatin adjuvant therapy for patients with pathologic stage II germ-cell tumors. Classic Papers and Current Comments: Highlights of Genitourinary Cancer Research 1998b;2:455–459. )| false
• Search Google Scholar
• Export Citation

International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers. International Germ Cell Cancer Collaborative Group. J Clin Oncol 1997;15:594–603.

• PubMed
International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers. International Germ Cell Cancer Collaborative Group. J Clin Oncol 1997;15:594–603. )| false
• Search Google Scholar
• Export Citation

Williams SD, Birch R, Einhorn LH et al.. Treatment of disseminated germ-cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide. N Engl J Med 1987;316:1435–1440.

• PubMed
WilliamsSDBirchREinhornLH. Treatment of disseminated germ-cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide. N Engl J Med 1987;316:1435–1440. )| false
• Search Google Scholar
• Export Citation

Bosl GJ, Geller NL, Bajorin D et al.. A randomized trial of etoposide + cisplatin vs vinblastine + bleomycin + cisplatin + cyclophosphamide + dactinomycin in patients with good-prognosis germ-cell tumors. J Clin Oncol 1988;6:1231–1238.

• PubMed
BoslGJGellerNLBajorinD. A randomized trial of etoposide + cisplatin vs vinblastine + bleomycin + cisplatin + cyclophosphamide + dactinomycin in patients with good-prognosis germ-cell tumors. J Clin Oncol 1988;6:1231–1238. )| false
• Search Google Scholar
• Export Citation

Einhorn LH, Williams SD, Loehrer PJ et al.. Evaluation of optimal duration of chemotherapy in favorable-prognosis disseminated germ-cell tumors: a Southeastern Cancer Study Group protocol. J Clin Oncol 1989;7:387–391.

• PubMed
EinhornLHWilliamsSDLoehrerPJ. Evaluation of optimal duration of chemotherapy in favorable-prognosis disseminated germ-cell tumors: a Southeastern Cancer Study Group protocol. J Clin Oncol 1989;7:387–391. )| false
• Search Google Scholar
• Export Citation

Jones RH, Vasey PA. Part II: testicular cancer—management of advanced disease. Lancet Oncol 2003;4:738–747.

• PubMed
JonesRHVaseyPA. Part II: testicular cancer—management of advanced disease. Lancet Oncol 2003;4:738–747. )| false
• Search Google Scholar
• Export Citation

Toner GC, Motzer RJ. Poor prognosis germ-cell tumors: current status and future directions. Semin Oncol 1998;25:194–202.

• PubMed
TonerGCMotzerRJ. Poor prognosis germ-cell tumors: current status and future directions. Semin Oncol 1998;25:194–202. )| false
• Search Google Scholar
• Export Citation

Loehrer PJ Sr, Lauer R, Roth BJ et al.. Salvage therapy in recurrent germ cell cancer: ifosfamide and cisplatin plus either vinblastine or etoposide. Ann Intern Med 1988;109:540–546.

• PubMed
LoehrerPJ SrLauerRRothBJ. Salvage therapy in recurrent germ cell cancer: ifosfamide and cisplatin plus either vinblastine or etoposide. Ann Intern Med 1988;109:540–546. )| false
• Search Google Scholar
• Export Citation

Motzer RJ, Geller NL, Tan CC et al.. Salvage chemotherapy for patients with germ-cell tumors. The Memorial Sloan-Kettering Cancer Center experience (1979–1989). Cancer 1991;67:1305–1310.

• PubMed
MotzerRJGellerNLTanCC. Salvage chemotherapy for patients with germ-cell tumors. The Memorial Sloan-Kettering Cancer Center experience (1979–1989). Cancer 1991;67:1305–1310. )| false
• Search Google Scholar
• Export Citation

McCaffrey JA, Mazumdar M, Bajorin DF et al.. Ifosfamide + cisplatin regimens as first-line salvage therapy in germ-cell tumors: response and survival (abstract). Proc Am Soc Clin Oncol 1996;14:Abstract 250.

• PubMed
McCaffreyJAMazumdarMBajorinDF. Ifosfamide + cisplatin regimens as first-line salvage therapy in germ-cell tumors: response and survival (abstract). Proc Am Soc Clin Oncol 1996;14:Abstract 250. )| false
• Search Google Scholar
• Export Citation

Loehrer PJ, Gonin R, Nichols CR et al.. Vinblastine plus ifosfamide plus cisplatin as initial salvage therapy in recurrent germ-cell tumor. J Clin Oncol 1998;16:2500–2504.

• PubMed
LoehrerPJGoninRNicholsCR. Vinblastine plus ifosfamide plus cisplatin as initial salvage therapy in recurrent germ-cell tumor. J Clin Oncol 1998;16:2500–2504. )| false
• Search Google Scholar
• Export Citation

Motzer RJ, Bosl GJ. High-dose chemotherapy for resistant germ-cell tumors: recent advances and future directions. J Natl Cancer Inst 1992;84:1703–1709.

• PubMed
MotzerRJBoslGJ. High-dose chemotherapy for resistant germ-cell tumors: recent advances and future directions. J Natl Cancer Inst 1992;84:1703–1709. )| false
• Search Google Scholar
• Export Citation

Beyer J, Kramer A, Mandanas R et al.. High-dose chemotherapy as salvage treatment in germ cell tumors: a multivariate analysis of prognostic variables. J Clin Oncol 1996;14:2638–2645.

• PubMed
BeyerJKramerAMandanasR. High-dose chemotherapy as salvage treatment in germ cell tumors: a multivariate analysis of prognostic variables. J Clin Oncol 1996;14:2638–2645. )| false
• Search Google Scholar
• Export Citation

Wood DP, Herr H, Motzer RJ et al.. Surgical resection of solitary metastases after chemotherapy in patients with non-seminomatous germ-cell tumors and elevated serum tumor markers. Cancer 1992;70:2354–2357.

• PubMed
WoodDPHerrHMotzerRJ. Surgical resection of solitary metastases after chemotherapy in patients with non-seminomatous germ-cell tumors and elevated serum tumor markers. Cancer 1992;70:2354–2357. )| false
• Search Google Scholar
• Export Citation

Pectasides D, Pectasides M, Farmakis D et al.. Gemcitabine and oxaliplatin (GEMOX) in patients with cisplatin-refractory germ cell tumors: a phase II study. Ann Oncol 2004;15:493–497.

• PubMed
PectasidesDPectasidesMFarmakisD. Gemcitabine and oxaliplatin (GEMOX) in patients with cisplatin-refractory germ cell tumors: a phase II study. Ann Oncol 2004;15:493–497. )| false
• Search Google Scholar
• Export Citation

Kollmannsberger C, Beyer J, Liersch R et al.. Combination chemotherapy with gemcitabine plus oxaliplatin in patients with intensively pretreated or refractory germ cell cancer: a study of the German Testicular Cancer Study Group. J Clin Oncol 2004;22:108–114.

• PubMed
KollmannsbergerCBeyerJLierschR. Combination chemotherapy with gemcitabine plus oxaliplatin in patients with intensively pretreated or refractory germ cell cancer: a study of the German Testicular Cancer Study Group. J Clin Oncol 2004;22:108–114. )| false
• Search Google Scholar
• Export Citation

De Giorgi U, Rosti G, Aieta M et al.. Phase II study of oxaliplatin and gemcitabine salvage chemotherapy in patients with cisplatin-refractory nonseminomatous germ cell tumor. Eur Urol 2006;50:1032–1038; discussion 1038–1039.

• PubMed
De GiorgiURostiGAietaM. Phase II study of oxaliplatin and gemcitabine salvage chemotherapy in patients with cisplatin-refractory nonseminomatous germ cell tumor. Eur Urol 2006;50:1032–1038; discussion 1038–1039. )| false
• Search Google Scholar
• Export Citation